Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The approval of two vaccines and a monoclonal antibody that target respiratory syncytial virus could shift the tide on the prevention and treatment of infection with this virus.
Nature Medicine explores the latest translation and clinical research news, with two separate groups announcing that genetically modified pig kidneys are functional in brain-dead human hosts.
Nigeria’s new mental health act establishes human rights protections for patients and promotes community-based care, offering a roadmap for other countries, despite ongoing challenges.
Addition of the COX inhibitor piroxicam to levonorgestrel, a standard emergency contraceptive, increased its efficacy without increasing adverse events.
VX-548 selectively inhibits peripheral sodium channels to reduce acute pain, with potentially fewer safety concerns than for existing, nonselective blockers.
Nature Medicine explores the latest translational and clinical research news, with early results from a phase 3 clinical trial of the GLP-1 receptor agonist semaglutide.
Researchers have identified a naturally occurring, non–genetically modified symbiotic bacterium that inhabits the gut of mosquitoes and prevents Plasmodium transmission.
Twenty years after completion of the Human Genome Project, genetics is rapidly being integrated into everyday clinical practice. But in this era of genomic revolution, genetically trained teams of healthcare workers are needed to optimize delivery of patient care.
AstraZeneca has introduced digital health solutions into clinical trials, demonstrating improved patient experience, accelerated timelines and reduced costs.
Nature Medicine explores the latest translation and clinical research news, with a phase 3 trial from Merck and Moderna testing mRNA-4157 combined with pembrolizumab in melanoma.
In a prospective study, artificial intelligence–assisted mammography screening had accuracy comparable to that of standard double reading — and substantially reduced radiologists’ workloads.